N/A
Completed N=94
The STEP 4Life Trial
Alzheimer Disease, At Risk · Alzheimer Disease, Protection Against · Dementia
Source: ClinicalTrials.gov NCT05069155 ↗
Enrolled (actual)
94
Serious AEs
0.0%
Results posted
Nov 2023
Primary outcomePrimary: Change in Mean Daily Steps From the Baseline Period to the End of the 12 Week Intervention Period. — 735; 2422 steps
Summary
The objective of this study is to test the feasibility of using behavioral economic interventions (gamification with social incentives) targeting daily step counts to prevent or delay the development of Alzheimer's Disease and Related Dementias (ADRD).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Mean Daily Steps From the Baseline Period to the End of the 12 Week Intervention Period. |
735; 2422 | — |
| SECONDARY Change in Mean Daily Step Counts During the 6 Week Follow-up Period After the End of the Intervention Period Tracked by Fitbit Inspire Device. |
705; 1983 | — |
Eligibility Criteria
Inclusion Criteria
- own a smartphone
- be enrolled in GeneMatch
- know their genetic testing results (APOE4)
- able to provide informed consent
Exclusion Criteria
- Inability to provide informed consent
- does not have daily access to a smartphone compatible with the wearable device and not willing to use a device that we can provide them
- already enrolled in another physical activity study
- unable to ambulate independently
- any other medical conditions that would prohibit participation in physical activity program
Data sourced from ClinicalTrials.gov (NCT05069155). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.